Syngene

Syngene's Q1 FY26 profit rose to Rs 87 crore as Research Services drove contract conversions, while operational revenue rose 11 per cent to Rs 875 crore

Bains further noted that after a subdued first half, impacted by a sector-wide downturn in US biotech funding, the second half of the year showed signs of recovery

During the quarter, Discovery Services launched "China+1" pilots with large and mid-size pharma companies and converted them into long-term contracts. Growth signals stabilizing

Contract research and manufacturing services firm Syngene International on Thursday said its profit after tax rose 17 per cent on-year to Rs 131 crore in the December 2024 quarter. The company had reported a profit after tax (PAT) of Rs 112 crore in the year-ago period. Revenue from operations rose to Rs 944 crore during the October-December quarter against Rs 854 crore in the third quarter of the preceding fiscal, Syngene International said in a statement. "The company's third-quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter," Syngene International MD and CEO Jonathan Hunt said. Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected, he added. Shares of the company ended 2.44 per cent higher at Rs 847.25 apiece on the BSE.

Short term trend of the Syngene remains strong as it is placed above its 5. 11 and 20 day EMA.

HDFC Life, CoForge and Syngene are the other 3 stocks trading in oversold zone; Technically a RSI reading below 30 on the charts is considered oversold; here are the key levels.

Syngene International shares ended the day's trade on BSE at Rs 694.2 apiece, down one per cent

Indian CDMOs are focusing on big biotech clients, and going forward, they believe the funding issues will not last long

Acquisition of Stelis facility saves $15 million in capex in FY24

Contract manufacturing services firm Syngene International on Wednesday said its profit after tax rose 21 per cent to Rs 179 crore during the March quarter. The Bengaluru-based firm had reported a Profit After Tax (PAT) of Rs 148 crore in the year-ago period. Revenue from operations rose to Rs 994 crore in the fourth quarter as compared with Rs 758 crore in the corresponding period of the last year, Syngene International said in a statement. For FY23, the company reported a PAT of Rs 464 crore, up 17 per cent, as against Rs 396 crore in the 2021-22 fiscal. Revenue from operations rose to Rs 3,193 crore in FY23 as compared with Rs 2,604 in 2021-22 fiscal. "All business divisions delivered growth through the year triggering investment in additional laboratory capacity and new facilities at our campuses in Bengaluru and Hyderabad, as well as creating over 1,000 new jobs," Syngene International Managing Director and CEO Jonathan Hunt said. Looking ahead, the company is optimistic abo

Contract manufacturing services firm Syngene International on Wednesday reported a 4 per cent decline in profit after tax to Rs 74 crore for the first quarter ended June 2022. The company had posted a PAT of Rs 77 crore in the April-June quarter of last fiscal. Its revenue from operations rose to Rs 644 crore in the first quarter against Rs 595 crore in the year-ago period, the company said in a statement. The first quarter results were against a strong quarter last year due to sales of Remdesivir, it added. Excluding the impact of Remdesivir, the underlying revenue from operations growth in the quarter stood at around 30 per cent year-on-year, it stated. "The first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. The contribution from the development and manufacturing services divisions drove the growth momentum against a low base in the previous year," Syngene International MD and CEO Jonathan Hunt ..

In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm's initiatives to overcome supply chain bottlenecks and other issues

Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive

In a Q&A, Jonathan Hunt talks about his company's capex plans and strategic initiatives going forward

Syngene International on Thursday said it has signed an agreement with Deerfield Discovery and Development Corporation (3DC)to collaborate for five years to advance therapeutic discovery projects.

While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger

The product will be launched once it receives approval from the Central Drugs Standard Control Organisation (CDSCO) next.

Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million square feet

Trading ideas by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers

Syngene, the contract research and manufacturing unit of Biocon is looking to expand its business to work on products for customers that target Indian consumers. It has signed up HerbalLife Nutrition, a nutrition company to develop nutrition based products that can be sold by the company in the country. This is the first nutrition research and development Lab in India by HerbalLife. The new facility is located in Syngene campus and has a separate Good Manufacturing Practices (GMP) formulation lab to support product testing, sampling and end-product development. The lab currently has 10 members combined from Syngene and HerbalLife. "Apart from bringing the global portfolio of products to India, we also endeavour to develop flavors that appeal to the Indian palate. Setting up the Nutrition R&D Lab in collaboration with Syngene will give us the ability to turnaround new products faster, and introduce them to the market quicker. This is the fifth dedicated centre and second for ...